// App-Quantinova.ai

7012 : A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

Researchers

Presenter

  • Curtis Andrew Lachowiez

Principal Investigators

  • Sanam Loghavi

  • Zhihong Zeng

  • Tapan M. Kadia

  • Lucia Masarova

  • Koichi Takahashi

  • George Dono Tippett

  • Samantha Smith

  • Jacqueline Suen Garcia

  • Prithviraj Bose

  • Elias Jabbour

  • Farhad Ravandi

  • Naval Guastad Daver

  • Guillermo Garcia-Manero

  • Bilyana Stoilova

  • Paresh Vyas

  • Hagop M. Kantarjian

  • Marina Konopleva

  • Courtney Denton Dinardo

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • MRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03471260

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved